{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:08:12Z","timestamp":1784113692689,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.seizure.2026.05.015","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:42:29Z","timestamp":1778758949000},"page":"10-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fenfluramine in developmental and epileptic encephalopathies: An age- and syndrome-stratified systematic review and meta-analysis"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-7492","authenticated-orcid":false,"given":"Helen Michaela","family":"de Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pandora Eloa Oliveira","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Oliveira","family":"de Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Pinzon","family":"Blaskoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-0768","authenticated-orcid":false,"given":"Pablo Ramon Fruett","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.seizure.2026.05.015_bib0001","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.015_bib0002","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2025.04.010","article-title":"Current and emerging precision therapies for developmental and epileptic encephalopathies","volume":"168","author":"Samanta","year":"2025","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.015_bib0003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-024-00546-6","article-title":"Developmental and epileptic encephalopathies","volume":"10","author":"Scheffer","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.seizure.2026.05.015_bib0004","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/epi4.12832","article-title":"Dravet syndrome: a systematic literature review of the illness burden","volume":"8","author":"Strzelczyk","year":"2023","journal-title":"Epilepsia Open"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.015_bib0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13023-023-02626-4","article-title":"The burden of illness in Lennox-Gastaut syndrome: a systematic literature review","volume":"18","author":"Strzelczyk","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.seizure.2026.05.015_bib0006","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1007\/s00431-024-05677-2","article-title":"The impact of developmental and epileptic encephalopathies on families: a qualitative study","volume":"183","author":"Velarde-Garc\u00eda","year":"2024","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.seizure.2026.05.015_bib0007","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1684\/epd.2021.1244","article-title":"Developmental and epileptic encephalopathies: recognition and approaches to care","volume":"23","author":"Raga","year":"2021","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2026.05.015_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.110067","article-title":"Neuromodulation strategies in developmental and epileptic encephalopathies","volume":"160","author":"Samanta","year":"2024","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2026.05.015_bib0009","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.neurom.2025.11.014","article-title":"Invasive neuromodulation in lennox-gastaut syndrome: a systematic review and meta-analysis","volume":"29","author":"de Oliveira","year":"2026","journal-title":"Neuromodulation."},{"issue":"8","key":"10.1016\/j.seizure.2026.05.015_bib0010","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/epi.18020","article-title":"Comprehensive scoping review of fenfluramine's role in managing generalized tonic-clonic seizures in developmental and epileptic encephalopathies","volume":"65","author":"Gil-Nagel","year":"2024","journal-title":"Epilepsia"},{"issue":"10216","key":"10.1016\/j.seizure.2026.05.015_bib0011","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.seizure.2026.05.015_bib0012","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.seizure.2026.05.015_bib0013","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/epi.17737","article-title":"Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo-controlled clinical trial","volume":"64","author":"Sullivan","year":"2023","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2026.05.015_bib0014","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with lennox-gastaut syndrome: a randomized clinical trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.seizure.2026.05.015_bib0015","series-title":"Cochrane handbook for systematic reviews of interventions version 6.4","author":"Higgins","year":"2023"},{"key":"10.1016\/j.seizure.2026.05.015_bib0016","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2026.05.015_bib0017","series-title":"GRADE handbook for grading quality of evidence and strength of recommendations","year":"2013"},{"issue":"10","key":"10.1016\/j.seizure.2026.05.015_bib0018","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"issue":"4","key":"10.1016\/j.seizure.2026.05.015_bib0019","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2013.285063","article-title":"How to use a subgroup analysis: users' guide to the medical literature","volume":"311","author":"Sun","year":"2014","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.seizure.2026.05.015_bib0020","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Borenstein","year":"2020","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.seizure.2026.05.015_bib0021","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/epi4.12623","article-title":"Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: a case series","volume":"7","author":"Aledo-Serrano","year":"2022","journal-title":"Epilepsia Open"},{"issue":"4","key":"10.1016\/j.seizure.2026.05.015_bib0022","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/epi.18241","article-title":"Fenfluramine treatment for Dravet syndrome: long term real-world analysis demonstrates safety and reduced health care burden","volume":"66","author":"Boncristiano","year":"2025","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2026.05.015_bib0023","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2026.05.015_bib0024","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/epi.16923","article-title":"Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder","volume":"62","author":"Devinsky","year":"2021","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2026.05.015_bib0025","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/epi4.13029","article-title":"Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: a retrospective and observational real-world study","volume":"9","author":"Gjerulfsen","year":"2024","journal-title":"Epilepsia Open"},{"issue":"4","key":"10.1016\/j.seizure.2026.05.015_bib0026","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/epi4.12624","article-title":"An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: a report from the Fenfluramine European Early Access Program","volume":"7","author":"Guerrini","year":"2022","journal-title":"Epilepsia Open"},{"issue":"7_supplement_1","key":"10.1016\/j.seizure.2026.05.015_bib0027","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000206359","article-title":"Healthcare Utilization and Persistence in Patients with Dravet Syndrome: a Retrospective Analysis Using U.S. Claims Data (P1-1.003)","volume":"102","author":"Jaganathan","year":"2024","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.seizure.2026.05.015_bib0028","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/epi.14540","article-title":"A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome","volume":"59","author":"Lagae","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.015_bib0029","first-page":"A62","article-title":"Fenfluramine treatment in adults with Dravet syndrome: experience so far from three UK centresJournal of Neurology","volume":"95","author":"Lisa","year":"2024","journal-title":"Neurosurgery & Psychiatry"},{"issue":"2","key":"10.1016\/j.seizure.2026.05.015_bib0030","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/epi.17854","article-title":"Fenfluramine below the age of 2 years in Dravet syndrome: what about safety and efficacy?","volume":"65","author":"Pietrafusa","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.015_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/epi4.70079","article-title":"Efficacy and tolerability of fenfluramine with concomitant potassium bromide in patients with Dravet syndrome","author":"Pringsheim","year":"2025","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.seizure.2026.05.015_bib0032","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ene.13195","article-title":"Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients","volume":"24","author":"Schoonjans","year":"2017","journal-title":"Eur J Neurol"},{"issue":"11","key":"10.1016\/j.seizure.2026.05.015_bib0033","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/epi.16690","article-title":"Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a real-world study","volume":"61","author":"Specchio","year":"2020","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2026.05.015_bib0034","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1111\/epi.17034","article-title":"Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany","volume":"62","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2026.05.015_bib0035","article-title":"Efficacy of low-dose fenfluramine on adult patients with lennox-gastaut syndrome","volume":"17","author":"Takeda","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.seizure.2026.05.015_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109620","article-title":"What have we learned from the real-world efficacy of FFA in DS and LGS? A post-marketing study in clinical practice","volume":"151","author":"Valls Carb\u00f3","year":"2024","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2026.05.015_bib0037","article-title":"Anti-seizure medications for Lennox-Gastaut syndrome","volume":"4","author":"Brigo","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.seizure.2026.05.015_bib0038","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/epi.12682","article-title":"Lennox-Gastaut syndrome and phenotype: secondary network epilepsies","volume":"55","author":"Archer","year":"2014","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2026.05.015_bib0039","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.seizure.2026.05.015_bib0040","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0361-9230(01)00615-3","article-title":"Serotonin and brain development: role in human developmental diseases","volume":"56","author":"Whitaker-Azmitia","year":"2001","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.seizure.2026.05.015_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108661","article-title":"The clinical, economic, and humanistic burden of Dravet syndrome - A systematic literature review","volume":"130","author":"Sullivan","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2026.05.015_bib0042","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.seizure.2021.02.025","article-title":"A systematic review of adults with Dravet syndrome","volume":"87","author":"Selvarajah","year":"2021","journal-title":"Seizure"},{"issue":"Suppl 3","key":"10.1016\/j.seizure.2026.05.015_bib0043","first-page":"S49","article-title":"Dravet syndrome: early electroclinical findings and long-term outcome in adolescents and adults","volume":"60","author":"Darra","year":"2019","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2026.05.015_bib0044","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/0976-3147.131657","article-title":"Assessment of topiramate's efficacy and safety in epilepsy","volume":"5","author":"Gupta","year":"2014","journal-title":"J Neurosci Rural Pract"},{"issue":"11","key":"10.1016\/j.seizure.2026.05.015_bib0045","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/epi.16638","article-title":"Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study","volume":"61","author":"Lai","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.015_bib0046","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejpn.2022.05.006","article-title":"Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: findings from serial echocardiographic assessments","volume":"39","author":"Agarwal","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2026.05.015_bib0047","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1111\/epi.13407","article-title":"Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine","volume":"57","author":"Ceulemans","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2026.05.015_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107091","article-title":"Fenfluramine treatment for Dravet syndrome: caregiver- and clinician-reported benefits on the quality of life of patients, caregivers, and families living in Germany, Spain, Italy, and the United Kingdom","volume":"190","author":"Jensen","year":"2023","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2026.05.015_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106976","article-title":"Fenfluramine treatment for dravet syndrome: real-world benefits on quality of life from the caregiver perspective","volume":"185","author":"Jensen","year":"2022","journal-title":"Epilepsy Res"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126001457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131126001457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:52:42Z","timestamp":1784112762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131126001457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":49,"alternative-id":["S1059131126001457"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2026.05.015","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenfluramine in developmental and epileptic encephalopathies: An age- and syndrome-stratified systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2026.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 British Epilepsy Association. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}